<DOC>
	<DOC>NCT01823900</DOC>
	<brief_summary>This study investigates safety and pharmacokinetic comparison of DWJ1276, a combination drug of Rosuvastatin and Olmesartan (test formulation), and co-administration of Rosuvastatin and Olmesartan (reference formulation) for single dose in healthy volunteers</brief_summary>
	<brief_title>Safety and Pharmacokinetic Comparison of Co-administration and a Combination Drug of Rosuvastatin and Olmesartan in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Healthy male volunteers between the ages of 20 and 50 and within 20% of their ideal body weight, without congenital abnormality or chronic disease History of cardiovascular, pulmonary, renal, endogenous, gastrointestinal, hematologic, neurologic or hemorrhagic disease; Clinically significant findings on routine laboratory (hematology, serum chemistry and urinalysis) or ECG tests; Use of prescription drugs in the 14 days immediately prior to starting the study that had the potential to interact with the study medication; Use of any substance that could induce or inhibit drug metabolism enzymes</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
</DOC>